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Abstract
The objective of this study was to identify, understand and generate a Taguchi orthogonal
array model for the formation of 10–50 μm microparticles with applications in topical/ocular
controlled drug delivery. Poly(lactic-co-glycolic acid) (PLGA) microparticles were fabricated
by the single emulsion oil-in-water method and the particle size was characterized using
laser diffraction and scanning electronic microscopy (SEM). Sequential Taguchi L12 and L18
orthogonal array (OA) designs were employed to study the influence of ten and eight param-
eters, respectively, on microparticle size (response). The first optimization step using the
L12 design showed that all parameters significantly influenced the particle size of the pre-
pared PLGA microparticles with exception of the concentration of poly(vinyl alcohol) (PVA)
in the hardening bath. The smallest mean particle size obtained from the L12 design was
54.39 μm. A subsequent L18 design showed that the molecular weight of PLGA does not
significantly affect the particle size. An experimental run comprising of defined parameters
including molecular weight of PLGA (89 kDa), concentration of PLGA (20% w/v), concentra-
tion of PVA in the emulsion (0.8% w/v), solvent type (ethyl acetate), organic/aqeuous phase
ratio (1:1 v/v), vortexing speed (9), vortexing duration (60 seconds), concentration of PVA in
hardening bath (0.8% w/v), stirring speed of hardening bath (1200 rpm) and solvent evapo-
ration duration (24 hours) resulted in the lowest mean particle size of 23.51 μm which was
predicted and confirmed by the L18 array. A comparable size was demonstrated during the
fabrication of BSA-incorporated microparticles. Taguchi OA design proved to be a valuable
tool in determining the combination of process parameters that can provide the optimal con-
dition for microparticle formulation. Taguchi OA design can be used to correctly predict the
size of microparticles fabricated by the single emulsion process and can therefore, ulti-
mately, save time and costs during the manufacturing process of drug delivery formulations
by minimising experimental runs.
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Introduction
Microparticles (MPs) may be designed to allow precise delivery of small quantities of potent
drug and increase the local concentration of the drugs in the target tissue [1, 2]. MPs for use in
drug delivery may be manufactured to provide controlled and sustained release, provide stabil-
ity to the encapsulated drug and may reduce the side-effects of the drug [2–4]. The fabrication
of MPs depends on the choice of suitable polymeric materials. An ideal polymeric material
must be non-toxic, biodegradable and biocompatible [4]. In this work, poly(lactic-co-glycolic
acid) (PLGA) was chosen for MP fabrication as it possesses the suitable properties, is readily
available and approved by regulatory authorities (i.e. FDA) for clinical use in humans [5]. In
the body, PLGA undergoes hydrolysis to generate lactic and glycolic acid which do not cause
carrier toxicity or immunological response and explains the success of PLGA as a biodegrad-
able polymeric material [6, 7]. When used for drug delivery, this hydrolysis leads to the degra-
dation of the PLGA matrix and any drug incorporated within is liberated in a time-dependent
fashion, typically over several weeks.
Various techniques are employed in the preparation of MP, including solvent emulsion
evaporation (single or double), spray drying, polymerization, and phase separation. These
techniques must fulfill certain standards which include the ability to achieve a controlled parti-
cle size and incorporate a required application-specific drug concentration [8–11]. Compara-
tive studies have shown that the solvent evaporation technique, a simple method requiring
only glassware and a magnetic stirrer is economical, convenient, robust and reproducible [12–
14]. This technique can therefore be used to provide preliminary information regarding the
parameters that influence the production of MP during scale up [14, 15]. The single emulsion
method comprises of an oil in water (o/w) emulsion process. This method uses on a volatile
organic solvent (e.g. dichloromethane (DCM); ethyl acetate (EAc)) containing dissolved poly-
mer and the drug to be loaded. This organic phase and an aqueous phase containing a dis-
solved surfactant (e.g. PVA) are emulsified to create an o/w emulsion (primary emulsion). A
surfactant is included in the aqueous phase to stabilize the organic droplets formed after the
emulsification process. These polymer droplets harden due to removal of the organic solvent
via dissolution and evaporation [16–20]. The process parameters involved in this method are
known to effect the physical properties of the MPs produced, such as particle size and disper-
sity [21]. The MP size is important in determining the drug release profile and mode of appli-
cation, such as the ability to pass through a needle. Furthermore, the particle size is vital with
respect to tissue irritation [6, 22]. Hence, there is a need for careful selection of the process
parameters in order to fabricate the most appropiate MP size.
Researchers have been able to identify several process parameters that influence the formu-
lation of MPs by changing one variable at a time to achieve the desired particle sizes [23]. How-
ever, this optimization method is inefficient, and thus costly, and a systematic approach based
on design of experiments (DOE) may be beneficial [23, 24]. The significance of optimization
methodology and DOE in research and development has been demonstrated in several studies
[20, 23–25]. DOE is a systematic technique used to determine the relationship between param-
eters affecting a method and the response produced by the process. The information allows the
researcher to identify and select the parameters and levels which have significant effects on the
final response/output. One such DOE methodology is Taguchi design [25].
Taguchi design is a statistical tool used to optimize parameters with complex interrelation-
ship. This design ascertains that not all parameters that cause variability can be controlled. The
design evaluates and identifies the controllable parameters that reduce the effect of the uncon-
trollable parameters (noise parameters) [24–26]. Furthermore, for Taguchi design, several
parameters can be analyzed at the same time with few experimental runs. Taguchi design uses
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an orthogonal array (OA) to estimate the effects of parameters on the response mean and
variation. An OA means the design is balanced so that parameter levels are weighted equally.
Hence, each parameter can be assessed independently of all the other parameters, and the
effect of one parameter does not affect the estimation of a different parameter. This makes it
more economical and efficient than conventional experimental methods (for example the
‘one-parameter-at-a time’ method) [23, 26–30]. Additionally, Taguchi design uses signal to
noise ratio (S/N ratio), a statistical measure of performance to evaluate the data for the
responses. This S/N ratio serves a purpose of measuring how the response varies relative to the
correct parameters and their optimal levels for the target value or range. The main goal of the
experiment constructed with Taguchi design is to find the best settings of control parameters
level involved in order to maximize the S/N ratio. Three available standard types of S/N ratios:
the smaller-the-better, the nominal-the-best, and larger-the-better are employed in Taguchi
design based on the desired response. The smaller-the-better is applied to minimise the
response, the nominal-the-best to target the response and the larger-the-better to maximise
the response [23–34]. The goal of this paper was to employ Taguchi OA designs to explore
the effect of process parameters on particle size using the single o/w evaporation technique to
obtain a drug delivery system for topical application.
Materials and methods
Materials
PLGA copolymers with lactic: glycolic acid ratios of 1:1 (MW: 29–38 kDa) were purchased
from Evonik (Darmstadt, Germany). PVA samples: 98% hydrolysed (MW: 13–23 kDa), 99+ %
hydrolysed (MW: 146–186 kDa), 99+ % hydrolysed (MW: 89–98 kDa), bovine serum albumin
(~66kDa) and QuantiPro Bicinchoninic Assay (BCA) kit were obtained from Sigma-Aldrich
(Poole, Dorset, UK). Anhydrous dichloromethane (� 99.8% with 50–150 ppm amylene as sta-
biliser) and ethyl acetate (� 99.5%) were purchased from Fisher Scientific (Loughborough,
Leicester, UK).
Experimental design
This study presents the application of Taguchi OA design to explore the effect of 10 processing
parameters on particle size using the solvent evaporation technique. These parameters were:
concentration of PVA, molecular weight of PVA, concentration of PLGA, type of solvent (i.e.
DCM, EAc), concentration of PVA in the hardening bath, stirring speed, ratio of organic/
aqueous phases, vortexing speed, duration of speed and time for solvent evaporation. The goal
was to generate a formulation model to produce 10–50 μm PLGA MP which has been sug-
gested to be to most suitable for topical and ocular applications. PLGA has a tailored biodegra-
dation rate and this is dependent on the copolymer ratio. PLGA of different lactide/glycolide
(copolymer) ratios; 50:50, 65:35, 75:25 and 85:15 lactide/glycolide are manufactured. The
65:35, 75:25 and 85:15 lactide/glycolide copolymers have extended degradation half-lives as
compared to 50:50 lactide/glycolide copolymers that have the fastest degradation half-life of
about 60 days [2, 5–7]. PLGA copolymers with lactide: glycolide ratios of 50:50 were utilized in
this research due to the proposed end-point therapeutic application.
Selection of parameters and levels. In a typical solvent evaporation technique, an exten-
sive number of processing parameters can influence the MP size (response). In this study, ten
parameters deemed experimentally controllable that influence particle size were identified by
critically assessing relevant literature and are listed in Table 1. Bible et al. [16] identified poly-
mer concentration, vortexing speed and duration, speed of hardening bath and PVA concen-
tration as possible important factors which affect particle size. Vyslouszil et al. [35] conducted
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the study of the influence of a stirring speed (600, 1000 rpm), PVA concentration (0.1%, 1%)
and organic solvent (DCM, EAc) during the formulation of drug-loaded PLGA microspheres.
Sharna, Madan and Lin [36] included homogenization speed, evaporation time, surfactant
concentration, organic/aqueous phase ratio, PLGA polymer type and concentration as process
parameters for the creation of paclitaxel-loaded biodegradable PLGA nanoparticles using
modified solvent evaporation method.
Taguchi OA design of experiments. Two types of Taguchi OA designs were imple-
mented to develop a model for optimal PLGA MP formulation to produce a particle size in the
range 10–50 μm. Taguchi design was employed to study only the main parameter effect. Tagu-
chi L12 (2
10) OA design (12, 2 and 10 represent the number of experiments, levels, and parame-
ters respectively) was initially employed to study ten parameters at two levels: low and high
(Table 1). The levels of the parameters were selected based on an established protocol by Bible
et al. [16]. The results produced by the L12 OA design were fed into the second design: the
parameters selection for Taguchi L18 (2
1) (37) OA design (18 = the number of experiments, 2
and 3 = levels, and 1 and 7 = the parameters) were guided by the analyses of a half-normal
plot, Pareto chart and response plot generated for the L12 OA design. In the L18 OA design,
the number of parameters was reduced to 8 and the number of levels for 7 parameters were
increased to 3: low, medium and high (Table 2). The L12 OA and L18 OA data generated by
design-expert software version 10 (Stat-Ease, Inc., USA) and measured responses are pre-
sented in Tables 3 and 4 respectively. Each row in these tables represents a formulation run
with the level of the parameters. The “X50” particle size value representing the median particle
diameter was taken as the response. All runs were performed in triplicate.
Table 1. Parameters and associated levels used in L12 design.
Parameter Name Units Levels
Low High
A Concentration of PLGA %w/v 10 20
B Solvent type - DCM EAc
C MW of PVA Da Low High
D Concentration of PVA in primary emulsion %w/v 0.3 1.2
E Vortexing speed scale 5 8
F Vortexing duration seconds 45 90
G Organic/aqueous phase ratio v/v 1:1 1:3
H Concentration of PVA in hardening bath %w/v 0.3 1.2
J Stirring speed rpm 400 900
K Solvent evaporation duration hours 18 24
https://doi.org/10.1371/journal.pone.0222858.t001
Table 2. Parameters and associated levels used in L18 design.
Parameter Name Units Levels
Low Medium High
A MW of PVA kDa 13 89 -
B Concentration of PLGA %w/v 15 20 30
C Concentration of PVA in primary emulsion %w/v 0.8 1.2 2.0
D Organic/aqueous phase ratio v/v 1:0.75 1:1 1:2
E Vortexing speed scale 3 5 9
F Vortexing duration seconds 60 90 120
G Stirring speed rpm 100 400 1200
H Solvent evaporation duration hours 20 24 48
https://doi.org/10.1371/journal.pone.0222858.t002
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Preparation of PLGA microparticles
PLGA MPs were fabricated using a single o/w emulsion technique. For the L12 design, 12 for-
mulation runs were applied to produce MPs of different sizes. Accordingly, 0.5 or 1.0 g of
PLGA were weighed and dissolved in 5 ml of DCM or EAc in a glass vial and incubated
overnight at 19 ˚C to form a PLGA solution. 3.0 or 12.0 g of either 13 or 146 kDa PVA were
Table 3. Combination of parameter levels of L12 OA design.
Run A
(%w/v)
B C
(Da)
D
(%w/v)
E
(scale)
F
(sec)
G
(v/v)
H
(%w/v)
J
(rpm)
K
(h)
Mean ± SD
(μm)
S/N ratio
1 10 DCM low 0.3 5 45 1:1 0.3 400 18 200.37 ± 2.82 -3.84
2 10 DCM low 0.3 5 90 1:3 1.2 900 24 100.7 ± 12.12 -3.34
3 20 EAc low 1.2 5 90 1:1 0.3 400 24 54.39 ± 4.37 -2.89
4 20 EAc high 0.3 5 45 1:1 1.2 900 18 162.12 ± 4.83 -3.68
5 20 DCM high 1.2 5 45 1:3 1.2 400 24 104.63 ± 0.85 -3.37
6 10 EAc low 1.2 8 45 1:3 1.2 400 18 97.27± 0.46 -3.31
7 20 DCM low 1.2 8 90 1:1 1.2 900 18 60.30 ± 1.29 -2.97
8 20 DCM high 0.3 8 90 1:3 0.3 400 18 102.16 ± 7.19 -3.35
9 10 EAc high 1.2 5 90 1:3 0.3 900 18 97.03 ± 0.08 -3.31
10 20 EAc low 0.3 8 45 1:3 0.3 900 24 61.99 ± 16.27 -2.99
11 10 DCM high 1.2 8 45 1:1 0.3 900 24 105.07 ± 1.73 -3.37
12 10 EAc high 0.3 8 90 1:1 1.2 400 24 95.04± 1.89 -3.30
Note. Low = Mw: 13–23 kDa, High = Mw: 146–186 kDa
https://doi.org/10.1371/journal.pone.0222858.t003
Table 4. Combination of parameter levels of L18 OA design.
Run A: A
(kDa)
B: B
(%w/v)
C:C
(%w/v)
D: D
(v/v)
E: E F: F
(sec)
G: G
(rpm)
H:H
(h)
Mean ± SD
(μm)
S/N ratio
1 13 15 1.2 1:1 5 90 400 24 49.76 ± 2.65 -2.83
2 89 30 0.8 1:2 5 120 200 24 45.48 ± 2.41 -2.76
3 13 20 2.0 1:2 3 60 400 24 60.84 ± 4.22 -2.97
4 89 20 2.0 1:0.75 5 120 400 20 41.12 ± 1.50 -2.69
5 89 15 1.2 1:0.75 3 120 1200 24 73.13 ± 0.52 -3.11
6 13 30 1.2 1:2 5 60 1200 20 44.94 ± 1.20 -2.75
7 89 15 2.0 1:1 5 60 200 48 25.83 ± 0.65 -2.35
8 13 30 0.8 1:1 3 120 400 48 67.09 ± 4.67 -3.04
9 13 20 1.2 1:1 9 120 200 20 24.01 ± 1.27 -2.30
10 13 30 2.0 1:0.75 9 90 200 24 50.81 ± 3.15 -2.84
11 13 15 2.0 1:2 9 120 1200 48 28.10 ± 1.26 -2.41
12 89 20 1.2 1:2 3 90 200 48 60.25 ± 6.09 -2.97
13 89 30 1.2 1:0.75 9 60 400 48 55.38 ± 1.07 -2.91
14 13 15 0.8 1:0.75 3 60 200 20 � �
15 89 15 0.8 1:2 9 90 400 20 47.46 ± 5.39 -2.79
16 89 20 0.8 1:1 9 60 1200 24 23.51 ± 0.81 -2.29
17 89 30 2.0 1:1 3 90 1200 20 � �
18 13 20 0.8 1:0.75 5 90 1200 48 40.38 ± 7.43 -2.68
Note.
� represents no creation of MPs
https://doi.org/10.1371/journal.pone.0222858.t004
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completely dissolved in 1 L deionized water heated at 90 ˚C using an IKA heated magnetic stir-
rer (RCT basic, UK) at 800 rpm, followed by filtration. A hardening bath was formed by trans-
ferring 200 ml of filtered 0.3 w/v or 1.2% w/v PVA solution into a 250 ml glass beaker with a
magnetic stirrer bar. 5 or 15 ml of the filtered 0.3 or 1.2% w/v PVA solution was added to the
10 or 20% w/v PLGA solution and shaken with Vortex-Genie1 2 at a scale of 5 or 8 for 45 or
90 s (Scientific Industries, lnc, NY, USA) to form an o/w emulsion. The o/w emulsion was
then added slowly to the hardening bath and stirred at either 400 or 900 rpm for 18 or 24 h
for complete evaporation of the organic solvent and hardening of the MPs. The MPs were har-
vested using Whatman-grade 1 filter paper under vacuum. MPs were then washed three times
with distilled water before being transferred to glass vials for freeze drying (MechaTech Sys-
tems Ltd, Bristol, UK) for 24 h.
The PLGA MPs in the L18 design were fabricated with the same single o/w emulsion tech-
nique and 18 different formulation runs were used. PVA solution at different concentrations
was prepared by completely dissolving 8.0, 12.0 or 20.0 g of either 13 or 89 kDa PVA in 1 L
deionized water. In order to form the o/w emulsion, 0.75, 1.0 or 1.5 g of PLGA were dissolved
in 5 ml of EAC and added to either 3.75, 5 or 10 ml of 0.8, 1.2 or 2.0% w/v PVA solution. The
solution was emulsified for 60, 90 or 120 s at a scale of either 3, 5 or 9. The o/w emulsion was
homogenized into the hardening bath consisting of 200 ml of 0.3% w/v PVA (MW 13 kDa).
The emulsion was stirred at either 100, 400 or 1200 rpm for 20, 24 or 48 h to ensure complete
organic solvent evaporation. The prepared MPs were collected, washed and dried in a freeze
drier for 24 h.
Protein-loaded microparticles
The model formulation produced by the initial Taguchi method was exploited in the fabrica-
tion of drug-loaded PLGA MPs. Bovine serum albumin (BSA) was used as the model protein
drug and conducted to validate the optimal locations of the parameter levels and also to inves-
tigate the effect of incorporated drugs on the particle size distribution. Briefly, 20 mg BSA was
dissolved in 5 ml of ethyl acetate in which 1 g of PLGA polymer was completely pre-dissolved.
A primary emulsion of the BSA/PLGA/EAc and PVA solution was formed and vortexed to
create the microparticles. Thereafter, the emulsion was added to a hardening bath for allow for
complete evaporation (24 hours). The supernatant was collected before the filtering, washing
and freeze-drying of the generated particles.
Encapsulation efficiency (EE%) and loading capacity (LC%) were evaluated, through the
indirect method of determining the amount of BSA in the supernatant, using Micro-Quanti-
Pro™ BCA Assay Kit (Sigma-Aldrich, Poole, Dorset, UK). Thereafter, a mass balance calcula-
tion was performed to determine the amount of BSA loaded into the microparticles. The EE%
and LC% were determined by the equations below:
EE% ¼
ðWeight of initial BSA added   Weight of free nonentrapped BSAÞ
Weight of initial BSA added
� 100
LC% ¼
Weight of BSA entrapped
Weight of BSA   loaded PLGAMP
� 100
Release profile determination
The in vitro protein release was determined using a method described by Determan et al, [37]
with slight modification. Briefly, 50 mg of BSA-loaded PLGA MP were suspended in 3 ml
of phosphate buffer saline (PBS). The samples were placed in a water bath at 37 ˚C and
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continuously stirred at 100 rpm. Sample volumes of (3ml) were collected at different times
within 14 days. Each time, fresh preheated PBS was reintroduced to maintain sink conditions.
The samples were centrifuged and the concentration of the protein in each sample was deter-
mined using Micro-QuantiPro™ BCA Assay kit.
Particle size/polydispersity analysis
The particle size distribution was measured by laser diffraction using a SymPatec HELOS
equipped with a RODOS/ ASPIROS dry dispenser (Germany). All measurements were per-
formed using the R5 (4.5 to 875 μm) and R3 (0.5 to 175 μm) lens for L12 and L18 designs
respectively. The particles were dispersed under a 4-bar pressure. About 5 mg of each sample
was placed in an ASPIROS glass vial. The particle size distribution (volume mean diameter,
X10, X50, X90) were analyzed with WINDOX 5 software (SymPatec, Germany).
Scanning electronic microscopy of MPs
Surface morphology, size, and shape of the MPs fabricated by formulation runs were obtained
using a scanning electron microscope (JOEL JCM-5700, USA). The dried MP samples were
deposited onto adhesive carbon tabs (Agar Scientific G3357N), which were pre-mounted onto
aluminum stubs (Agar Scientific JEOL stubs G306). The samples were gold sputtered for 60 s
to attain a thickness of approximately 30 nm (Quorum SC7620). The morphologies of the MP
samples were analysed at magnifications of X100, and X500.
Statistical analysis
The experimental design results were statistically analysed using Design-Expert software ver-
sion 10.0.5.0 (Stat-ease- Inc., Minneapolis). Response and interaction plots were generated to
examine the effect of parameter levels on the mean response (particle size). Half-normal plots
and Pareto charts were generated to guide the selection of parameters for the final optimal
model. The data were assessed by ANOVA combined with Fisher’s statistical test (F- test) to
determine whether a chosen parameter had a significant effect on the desired value (p< 0.05).
The S/N ratio formula below (i.e. smaller-the-better) was used to evaluate the response values.
All data presented were expressed as mean and standard deviation (SD).
S
N
ratio ¼   10 � log
P
ðY2Þ
n
where Y is the mean and n is the number of experiments.
Results
Microparticle formulation: L12 OA design
The Taguchi design DOE approach was explored to identify the process parameters in the
solvent evaporation technique with the most significant effects on PLGA MP size and to gen-
erate a predictive model. L12 OA design was used as the first optimization step in the DOE.
The parameters and their levels for the L12 OA design (Table 1) were selected based on previ-
ous studies using the solvent evaporation method for MP fabrication [16, 34–36]. From the
design, ten parameters at two levels were investigated, namely; concentration of PLGA (A),
solvent type (B), MW of PVA (C), concentration of PVA in primary emulsion (D), vortexing
speed (E), vortexing duration (F), organic/aqueous phase ratio (G), concentration of PVA in
hardening bath (H), stirring speed of the hardening bath (J), and solvent evaporation dura-
tion (K), with particle size as a response. This design resulted in 12 formulation runs (36
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runs in total; three replicate for each run). PLGA MPs were then successfully fabricated
using the 10 parameters combinations. Table 3 shows the parameter levels combinations
computed by design-expert software for L12 OA design and the median particle size mea-
surement by laser diffraction using a SymPatec HELOS equipped with a RODOS/ ASPIROS
dry dispenser (Germany). The rows represent the formulation runs and the column repre-
sents the parameters. All the level settings in each formulation run appeared an equal num-
ber of time: for each parameter, low level and high level appeared 6 times. The data with the
average median particle size ranging from 54.39 to 200.37 μm was produced for the design.
The data had a mean of 103.42 ± 41.55 μm. None of the runs produced MPs within the goal
range of 10–50 μm. Nonetheless, Run 3 (54.39 μm) created MPs with smallest median parti-
cle size closed to the upper range value. MPs with smallest median diameter were obtained
from an organic phase comprising of EAc and 20% w/v PLGA polymer, and an aqueous
phase of low molecular weight of 1.2% w/v PVA which were combined at a ratio of 1:1 to
form a primary emulsion by a vortexing speed at scale 5 for 90 s. The emulsion was intro-
duced to a hardening bath of 0.3% w/v PVA at a speed off 400 rpm and the MPs created
were hardened at complete solvent evaporation for 24 h (Run 3). The largest particle size was
registered with 10% w/v PLGA concentration, DCM, 0.3% w/v (low MW) PVA in primary
emulsion, vortexing speed at scale 5, vortexing duration of 45 s, 1:1 organic/aqueous phase
ratio, 0.3% w/v PVA in hardening bath, 400 rpm stirring speed and 18 h evaporation dura-
tion (Run 1).
Statistical data analysis (L12 OA design). S/N ratio was computed for each of the for-
mulation run with the smaller-the-better particle size characteristic (Table 3). High S/N
ratio value was recorded for formulation Run 3 (-2.89). A half-normal probability plot was
generated by using the estimated effects of the parameters to help assess the important and
unimportant parameters (Fig 1). The following parameters: vortexing duration, concentra-
tion of PVA in emulsion, solvent evaporation duration, vortexing speed, concentration of
PLGA, organic/aqueous phase ratio, solvent type, molecular weight of PVA and stirring
speed are found at the right side of the plot and parameters: concentration of PVA in hard-
ening bath and interaction between concentration of PLGA and solvent type lined up on
the yellow error line. A Pareto chart was generated to identify the magnitude of the chosen
effects for the model formulation (Fig 2). It was observed that all bars of the parameters are
above the t-test (reference line) except the concentration of PVA in the hardening bath and
interaction between the concentration of PLGA and solvent type. The white column seen
inside the bars indicates that the parameters have significant effect on the mean particle size.
Table 5 displays the ANOVA results for the particle size of the MP to study the significant
parameters included in the model. F-test was carried out on the experimental data and a
value of 7880.15 was obtained. All the parameters chosen for the model have significant
effects on the MP size. From Table 5, vortexing speed had the maximum contribution to the
total variance (21.60%) and the least was stirring speed for the hardening process (1.95%).
Additionally, a diagnostic analysis was performed by generating the response plots for the
10 parameters to evaluate the influence of each average parameters levels on the mean parti-
cle size (103.4 μm) (Fig 3). The plot for levels of the concentration of PVA in hardening
bath shows a negligible effect on the particle size. However, the plots for the remaining
parameters show the high levels affecting the particle size significantly except the MW of
PVA with the low level having an influence on the particle size. Fig 4 is the interaction plot
for parameter A and B displaying parallel lines to indicate no influence on the mean particle
size. The results obtained in the plots (Figs 3 and 4) are the same as the results presented in
the ANOVA table.
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Microparticle formulation: L18 OA design
The L12 OA design identified 9 important parameters: concentration of PLGA, solvent type,
MW of PVA, concentration of PVA in primary emulsion, vortexing speed, vortexing dura-
tion, organic/aqueous phase ratio, stirring speed of the hardening process and solvent evapo-
ration duration that significantly influence the particle size of MP as such can be controlled.
These results were fed into a second design, L18 OA design to further ascertain how these
parameters determine the particle size of MP by introducing a third level for each of the
important parameters excluding parameter C (i.e. solvent type). Eight parameters: MW of
Fig 1. Half-normal % probability versus standardized effects plot after selection of parameters for the model. The yellow line
represents the error line. Positive effects represent parameters with positive standardized values and negative effects signify
parameters with negative standardized values. Plot generated for L12 OA design parameters: stirring speed (J), molecular weight of
PVA (C), solvent type (B), organic/aqueous phase ratio (G), concentration of PLGA (A), vortexing speed (E), solvent evaporation
duration (K), concentration of PVA in emulsion (D), vortexing duration (F).
https://doi.org/10.1371/journal.pone.0222858.g001
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PVA (A), concentration of PLGA (B), concentration of PVA in primary emulsion (C),
organic/aqueous phase ratio (D), vortexing speed (E), vortexing duration (F), stirring speed
of the hardening process (G) and solvent evaporation duration (H) were considered for the
L18 OA design. The parameter levels as seen in Table 2 were based on formulation Run 3 as
Fig 2. Graph of t-value of absolute effects verses rank. This is an ordered bar chart, which shows the magnitude of the chosen
parameters for the model. The bars above the t-value (the reference line) with white represent the significant effects and the bars
below the reference line are insignificant. Data generated for L12 OA design parameters: vortexing duration (F), concentration of
PVA in emulsion (D), solvent evaporation duration (K), vortexing speed (E), concentration of PLGA (A), organic/aqueous phase
ratio(G), solvent type (B), molecular weight of PVA (C) and stirring speed for hardening process (J).
https://doi.org/10.1371/journal.pone.0222858.g002
Table 5. ANOVA for L12 OA design.
Source Sum of Squares Degree of freedom (df) Mean Square F Value p-value
Prob. > F
% Contribution
Model 18986.23 9 2109.58 7880.15 0.0001 -
A 1872.25 1 1872.25 6993.62 0.0001 9.86
B 925.59 1 925.59 3457.45 0.0003 4.87
C 690.54 1 690.54 2579.44 0.0004 3.64
D 3457.47 1 3457.47 12915.06 < 0.0001 18.21
E 3247.56 1 3247.56 12130.96 < 0.0001 17.10
F 4100.71 1 4100.71 15317.84 < 0.0001 21.60
G 1073.71 1 1073.71 4010.75 0.0002 5.66
J 370.19 1 370.19 1382.79 0.0007 1.95
K 3248.22 1 3248.22 12133.42 < 0.0001 17.11
Residual 0.5354 2 0.2677 - - -
Corr. Total 18986.76 11 - - - -
https://doi.org/10.1371/journal.pone.0222858.t005
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this generated the smallest particle size closed to the target range. The solvent type (EAc and
PVA) concentration in the hardening process (0.3% w/v) were kept constant for all the for-
mulation runs. The particle sizes were measured by laser diffraction technique. Table 4
shows the L18 design generated by the design-expert software and the particle size obtained
for each formulation run. A data of 18 formulation runs with 8 parameters was constructed,
in each of the parameters column, the levels low, medium or high occurred 9 times. The 16
formulation runs within this design produced particle size range of 23.51–73.13 μm and a
mean particle size of 48.32 μm. Runs 14 and 17 failed completely and no MPs were created.
These formulation runs failed using scale 3 as the vortexing speed to homogenize the o/w
emulsion. Looking at Table 4 most of the MP created from this design have particle size
within the target range apart from Run 3 (60.84 μm), Run 5 (73.13 μm), Run 8 (67.04 μm),
Run 10 (60.25 μm) and Run 12 (55.38 μm). MPs formulated with Runs 3, 5, 8 and 10 had
large particle size by using vortexing speed at the low level (scale 3). The goal of the study
was to generate the smallest particle size within the range 10–50 μm, the smallest particle size
23.51 μm (PDI = 1.09 ± 0.01) was achieved by formulation Run 16 and the cumulative size
distribution curves for this run are shown in Fig 5. SEM images were taken to visualise the
surface morphology of the MP formulation Run 16 selected from L18 OA design as the opti-
mal model formulation for this study. The SEM images of the MP samples are shown in Fig
6. The images shows that each sample are made of a range of spherical microparticles and
these confirm the particle size measurements. The data for the SEM and the size distributions
were compared to the formulation Run 3 in L12 OA design.
Statistical data analysis (L18 OA design). Table 4 summarises the S/N ratio evaluated for
each of the formulation runs. The largest value based on the smaller-the-better analysis was
Fig 3. Response (main effects) plots for the average effects of the 10 process parameters (A, B, C, D, E, F, G, H, J and K) on the
mean particle size for the L12 OA design. The vertical axis shows the mean particle size (μm) and the horizontal axis shows two
levels (low and high) of the process parameters. The red dashed line represents the value of the total mean of the particle size.
https://doi.org/10.1371/journal.pone.0222858.g003
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Fig 4. Interaction graph plot showing the effect of concentration of PLGA (w/v) and solvent type on the mean particle size
(μm).
https://doi.org/10.1371/journal.pone.0222858.g004
Fig 5. Cumulative size distribution of PLGA MP fabricated with ethyl acetate as organic solvent: (A) formulation Run 3 from
L12 OA design and (B) formulation Run 16 from L18 OA design identified as the optimal model formulation (n = 3).
https://doi.org/10.1371/journal.pone.0222858.g005
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produced by Run 16 (-2.29). Fig 7 displays the half-normal plot generated by the design-expert
software to assess which of the parameters are important and which are unimportant. The
parameters: vortexing speed, concentration of PLGA, organic/aqueous phase ratio, stirring
speed, concentration of PVA in primary emulsion, vortexing duration and solvent evaporation
duration are seen at the far right of the error line. The parameter MW of PVA is located on the
error line. The ANOVA for the selected parameters: concentration of PLGA, concentration of
PVA in primary emulsion, organic/aqueous phase ratio, vortexing speed, vortexing duration,
stirring speed of the hardening process and solvent evaporation duration is summarized in
Fig 6. SEM images of PLGA MP formulated by (A) run 3 from L12 OA design and (B) run 16 from L18 OA design (optimal
model formulation) and (C) BSA-loaded PLGA MP.
https://doi.org/10.1371/journal.pone.0222858.g006
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Table 6 and it shows all parameters selected for the model have significant effects on the parti-
cle size (p>0.05). A high value of F (12261.0) was obtained for the model (1.68%). The sum
of squares shows that 32.79% of the total variance is established by the vortexing speed. The
parameter with the least contribution is solvent evaporation duration. Fig 8 shows the response
plots for the average parameter levels of the L18 design. No influence is observed for the two
Fig 7. Half-normal % probability versus normal effects plot after selection of parameters for the model. Pink line
represents error line. Data generated for L18 OA design parameters: vortexing speed (E), concentration of PLGA (B),
organic/aqueous phase ratio (D), stirring speed (G), concentration of PVA in emulsion (C), vortexing duration (F) and
solvent evaporation duration (H).
https://doi.org/10.1371/journal.pone.0222858.g007
Table 6. ANOVA for L18 OA design.
Source Sum of
Squares
df Mean
Square
F
Value
p-value
Prob. > F
%
Contribution
Model 3504.60 14 250.33 12261.00 0.0071
B-B 336.50 2 168.25 8240.73 0.0078 9.60
C-C 83.86 2 41.93 2053.66 0.0156 2.39
D-D 249.47 2 124.74 6109.56 0.0090 7.12
E-E 1149.15 2 574.58 28142.50 0.0042 32.79
F-F 62.67 2 31.34 1534.89 0.0180 1.79
G-G 193.63 2 96.82 4742.02 0.0103 5.53
H-H 58.75 2 29.38 1438.86 0.0186 1.68
Residual 0.0204 1 0.0204 - - -
Corr. Total 3504.62 15 - - - -
https://doi.org/10.1371/journal.pone.0222858.t006
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levels of the MW of PVA. The concentration of PLGA response shows medium level (20% w/
v) having the largest influence on the mean particle size followed by the low level (15% w/v)
and then the high level (30% w/v). The plot for the concentration of PVA in primary emulsions
displays 2.0% w/v (high level) with the most significant effect and the 1.2% w/v (medium level)
with the least. The medium level (1:1) for the organic/aqueous phase ratio increased the mean
particle size while the high level (1:3) and low level (1:0.75) decreased the response accordingly.
As the level increases in the vortexing speed parameter, the effect on the mean particle size
increases. In the plot for vortexing duration, the low level (60 seconds) and the high level (120
seconds) have an equal and larger influence on the mean particle size. Parameters: stirring
speed and solvent evaporation duration have the same pattern for levels influence on the mean
particle size i.e. low> high > medium implies a reduction in the effect.
Characterization of BSA-loaded PLGA MP
BSA-loaded PLGA MPs were successfully generated using the parameters derived from the
optimal model formulation. The average particle size was determined as 22.79 ± 0.08 with
a PDI of 1.13 ± 0.04, which is not significantly different than the unloaded microparticles
(p> 0.05 by t-test). The average EE% and LC% (of the BSA protein) in these MPs were quanti-
fied as 56.37 ± 1.26 and 15.03 ± 0.89, respectively. In addition, SEM analysis of the BSA-loaded
PLGA MP further confirmed the results obtained from the particle size analysis and also docu-
mented the spherical shape of these MPs (Fig 6). The in vitro release profile of the incorporated
protein from the BSA-loaded PLGA MP is summarized in Fig 9 where it can be seen that a
steady-rate of release is maintained over a period of 13 days, at which >90% of total BSA is
released from the MPs.
Discussion
The solvent evaporation method has been used widely to encapsulate drugs in polymer matri-
ces to form delivery systems and involves many processing parameters which influence the
Fig 8. Response plots for the average effects of the 8 process parameters (A, B, C, D, E, F, G and H) on the mean particle size for
the L18 OA design. The vertical axis shows the mean particle size (μm) and the horizontal axis shows three levels (low, medium and
high) of the process parameters. The red dashed line represents the value of the total mean of the particle size.
https://doi.org/10.1371/journal.pone.0222858.g008
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properties and quality of the final MPs product [12–16]. Optimising this process one variable
at a time is impractical. As such, this study employed the use of a Taguchi orthogonal arrays
design of experiment protocol to assess the optimal conditions required for the fabrication of
10–50 μm sized MPs and to identify the parameters that deemed to most significantly influ-
ence PLGA MP size.
The first optimization step in this study was the implementation of L12 OA design to evalu-
ate 10 parameters at two levels (low and high) and identify the parameters having influence on
particle size. This design is meant for evaluating the effect of 10 independent parameters, each
having two level values. This design assumes that there is no interrelatioship between any two
parameters. However, a clear evidence of interaction was observed between concentration of
PLGA and solvent type, although this interaction had no effect on the particle size. This is
because in each formulation run the PLGA polymer was dissolved in a constant volume (5 ml)
of solvent type stated in the run. The mean particle sizes (response) for the 12 experiments
were in a range of 54.39–200.37 μm as shown in Table 3. MPs with the largest particle size
(200.37 μm) were formulated with Run 1 when all the 10 parameters had been used in their
lowest levels. The smallest mean particle size (54.39 ± 4.37 μm) was obtained from Run 3 in
which the concentration of PLGA, solvent type, concentration of PVA primary emulsion, vor-
texing duration, and solvent evaporation duration were ‘high’ and the molecular weight of
PVA, vortexing speed, organic/aqueous phase ratio, concentration of PVA in hardening bath
and stirring speed during the hardening process were at their low level. In this experiment, a
smaller-the–better response (particle size) was desirable and the S/N ratio was calculated for
each of the 12 experiments run in order to evaluate the data and identify the best set of param-
eters levels to generate the smallest particle size. Form the results, formulation Run 3 produced
the smallest particle size (54.39 μm) with the highest S/N ratio value (-2.89).
Fig 9. The in vitro release of BSA from MP prepared with the optimal model formulation. Results are described as
mean± SD, n = 3.
https://doi.org/10.1371/journal.pone.0222858.g009
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The L12 OA design results were statistically analysed using design-expert software (version
10). This software is able to screen each parameter with respect to their influence on the parti-
cle size characteristic. A half-normal plot is one of the tools used in this software by identifying
the important parameters and any interactions. This plot uses the magnitude of the estimated
effects for the main parameters and any interactions in order to evaluate the important and
unimportant parameters, and order the parameters from the most important down to the least
important. Important parameters have their estimated effects completely removed from zero,
while unimportant parameters have near-zero effects [38]. From Fig 1, the parameters located
at the far right of the error lines are the important parameters and parameter F(vortexing
speed) can be considered to have the maximum independent effect on particle size. Concentra-
tion of PVA in hardening bath and the interaction between the concentration of PLGA and
solvent types that are lined up on the error line are unimportant, have zero or near zero effect
on the particle size and excluded from the model. In Fig 1, the orange colour represents the
parameter that has a positive effect and the blue represents parameter with negative effect on
the mean particle size. In addition, a Pareto chart was created to identify the magnitude of the
chosen parameters effects for the model (Fig 2). The bars above the t- critical value (the refer-
ence line) with white represent the important parameters that can possibly be included in the
model and the bars below the reference line are unimportant. The white column seen inside
the bars indicates that the parameters have significant effect on the mean particle size. F-test
was carried out on the experimental data. The ANOVA for the selected model summarised in
Table 5 showed that the model F value of 7880.15 was significant and that there was only
0.01% likelihood the variations among the mean particle size of the parameters is due to noise.
Furthermore, a p-value of less than 0.05 indicates that the model terms are significant at the
probability level of 95%. All the parameters chosen for the model have very significant effects
on the microparticle size. From Table 5, vortexing speed had the maximum contribution
(21.60%) and the least was stirring speed for the hardening process (1.95%). This evaluation is
confirmed in the data presented in the Pareto chart (Fig 2).
The effect of each parameter on the mean paricle size are clearly observed in the response
plots (Fig 3). The plots illustrate the average of each particle size for each level of each parame-
ter and display the parameter with the largest effect. From the plots, the concentration of PVA
in hardening bath (H) has negligible effect on the mean particle size. However, the remaining
parameters show significant effects on the mean particle size as already evaluated by AVOVA
and the Pareto chart. As shown in Fig 3, increasing the vortexing duration (F) produced a
small particle size. An extended duration of vortexing may allow for better dispersal of the oil
phase to form fine droplets which then harden to form MPs [39, 40]. The effective creation of
a primary emulsion and the stability of the droplets during the emulsification depends on the
presence of surfactant, in this case PVA, at the interface between the aqueous and organic
phases, lowering interfacial tension and providing a barrier to coalescence [35,36,40]. Increas-
ing the PVA concentration in the primary emulsion (D) from 0.3% w/v to 1.2% w/v resulted
in a decrease in the mean particle size (Fig 3). As shown in the figure, an increase in the solvent
evaporation duration (K) resulted in a decrease in mean particle size. It is possible that at the
low level solvent removal from the droplet is incomplete, and that a longer duration allows for
removal of any residual solvent expanding the polymer network. Vortexing speed (E) was a
parameter of primary importance in the homogenization step because energy is required
to disperse the organic phase in the aqueous phase [39]. The results showed that the mean
particle size was inversely proportional to the vortexing speed; increase in vortexing speed
decreased the MP size because the emulsion was dispersed into smaller droplets at a higher
scale. This observation is line with the studies of Sharma, Madan and Lin [36]. The response
plot for PLGA concentration (A) in the figure clearly shows that particle size decreased at
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higher PLGA concentration and may be as a consequence of PLGA surface activity. In this
study two organic/aqueous phase ratios (G) were evaluated (1:1 and 1:3). The higher continu-
ous phase volume may allow for a greater distance between dispersed oil droplets, reducing
the rate of collision and coalescence [41, 42]. As observed in Fig 3, microparticles prepared
with solvent type (B), EAc were characteretized by their smaller particle size and most likely
due to the result of increased water solubility. The response plot for MW of PVA (C) shows
that increasing the molecular weight increases the microparticle size and may be attributed to
the increased viscosity of the solution reducing shear during emulsification [43, 44]. Stirring
speed is one of the parameters that is well documented to have significant effect on particle
size [16, 36, 37, 45–49]. Increasing stirring speed produces microparticle with small sizes by
improved dispersal of the oil phase. This observation is confirmed in this study. In the effect
of stirring speed (J) plot, the particle size decreased with increased in stirring speed from 400
rpm to 900 rpm.
From the analysis of the L12 OA design, 9 parameters were identified as important to be
included in the formulation model but 8 parameters were used for the L18 OA design: this
“exclusion” was based on the fact that the solvent used i.e. ethyl acetate is less polar than
DCM and so there was no justification for considering a more polar solvent for further anal-
yses. As such, the L18 OA design parameters included: concentration of PLGA (B), concen-
tration of primary emulsion (C), organic/aqueous phase ratio (D), vortexing speed (E),
vortexing duration (F), stirring speed (G) and solvent evaporation duration (H) at three lev-
els: low, medium and high and 1 parameter: molecular weight of PVA (A) at two levels: low
and high (Table 2). The parameters levels ranges were selected based on the levels of the Run
3 formulation in L12 OA design. Table 4 represents the L18 OA generated by design- expert
software and the mean particle size measured for each of the 18 experimental runs. The
mean particle size range obtained was 23.51 to 73.13 μm. From the Fig 5, the generated half
normal plot shows, vortexing speed, concentration of PLGA, organic/aqueous phase ratio,
stirring speed, concentration of PVA in emulsion, vortexing duration and solvent evapora-
tion duration as the important parameters for the model. In the figure, the orange colour
indicates the parameters have positive effect on the mean particles size. ANOVA has shown
that the parameters have a significant effect (Model F value = 12261.0, p < 0.05) on the mean
particle size (Table 6). There is only 0.71% likelihood that this large model F value could
occur due to noise. Except for the MW of PVA, all other parameters do significantly influ-
ence the mean particle size. From these analyses, the major paramenter affecting the particle
size is vortexing speed (E) with 32.79% and the least ranking parameter is solvent evapora-
tion duration, 1.68% (H).
The influence of each parameter on the mean particle size are clearly observed in the
response plots (Fig 7). The effect of MW of PVA (A) on the particle size is negligible. The
results show that increasing the vortexing speed (E) from scale 3 to scale 9 reduced the parti-
cle size. Changing the concentration of PLGA (B) and the organic/aqueous phase ratio (D)
from a low level of to meduim level decreased the particle size. However, an increase to high
level caused an increasing effect on the particle size. The low and high levels of parameters:
stirring speed (G), PVA concentration in primary emulsion (C), vortexing duration F)
and solvent evaporation duration reduce the particle size. Whereas the medium levels have
increased the particle size. Crucially, the shape of the fabricated (spherical) MPs do not
change with the different parameters/within each Run. Microparticulate formulations are
often considered in respect to the development of a drug delivery system for clinical applica-
tions. Herein, we additionally assessed the robustness and predictive ability of the Taguchi
OA design of experiment methodology in the fabrications of the BSA-loaded MPs. BSA,
~66KDa, is a stable, globular and relatively non-reactive protein that is often used as a
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model protein in drug MP development studies [50]. As such, data presented in this study
demonstrate that following sufficient entrapment of BSA within the MPs (i.e. >56% encap-
sulation efficiency), no significant changes in size occur- in agreement with the Taguchi
L18 OA assessment. This aspect further validates the DOE technique as a feasible predictive
tool for pharmaceutical formulation- especially in the context of biological entrapment e.g.
growth factors, antibodies, biologicals.
Taken together, these results highlight the complexity of the MP fabrication process and the
clear benefits of a DOE approach. The optimal model formulation was identified to be Run 16
from the L18 OA design. The mean particle size was found to be 23.51 μm which falls ino the
required range of 10–50 μm. The parameters and the associated level for the optimal model
formulation are molecular weight of PVA = 89,00Da (high), concentration of PLGA = 20 w/v
% (medium), organic/aqueous phase ratio = 1:1 (medium), vortexing speed = 9 (high), vortex-
ing duration = 60 seconds (low), stirring speed for hardening process = 1200 rpm (high) and
solvent evaporation duration = 24 h (medium).
Conclusion
In this study, Taguchi OA design proved to be a valuable tool in the optimization of several
processing parameters in solvent evaporation technique with complex interrelationship with
few experiments. The design was efficient for identifying the parameters which had significant
effect on microparticles size More precisely, vortexing speed, concentration of PLGA, organic/
aqueous phase ratio, stirring speed, concentration of PVA in primary emulsion, vortexing
duration were significant whereas the molecular weight of PVA and concentration of PVA
in hardening bath were proven to be not important parameters with regard to PLGA micro-
particle size. The optimal model formulation was established as molecular weight of PVA =
89,00 Da, concentration of PLGA = 20 w/v %, organic/aqueous phase ratio = 1:1, vortexing
speed = 9, vortexing duration = 60 s, stirring speed for hardening process = 1200 rpm and sol-
vent evaporation duration = 24 h. These optimum levels of the parameters were useful in the
fabrication of PLGA microparticles with the minimum particle size of 23.51 μm. A model drug
(BSA) was successfully incorporated into the optimised microparticles, which had no statisti-
cally significant impact on size.
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